Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease

被引:15
|
作者
Lee, Brian P. [1 ]
Vittinghoff, Eric [2 ]
Pletcher, Mark J. [2 ]
Dodge, Jennifer L. [2 ]
Terrault, Norah A. [3 ]
机构
[1] Univ Calif San Francisco, Dept Gastroenterol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
[3] Univ Southern Calif, Div Gastrointestinal & Liver Dis, 1450 San Pablo Ave,HC4 Room 3054, Los Angeles, CA 90033 USA
关键词
D O I
10.1002/hep.31027
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims In some states, liver transplantation (LT) for alcohol-associated liver disease (ALD) is covered by Medicaid only with documentation of abstinence and/or alcohol rehabilitation. Different Medicaid policies may affect the distribution of LT for ALD, particularly post-2011, as centers have adopted early (i.e., specific abstinence period not required) LT practices. Approach and Results We surveyed Medicaid policies in all states actively performing LT and linked state policies to prospectively collected national registry data on LT recipients from 2002 to 2017 with ALD as the primary listing diagnosis. We categorized Medicaid policies for states as "restrictive" (requiring documentation of a specific abstinence period and/or rehabilitation) versus "unrestrictive" (deferring to center eligibility policies). Difference-of-differences analysis, comparing 2002-2011 versus 2012-2017, evaluated whether restrictive policies were associated with decreased proportion of LTs paid by Medicaid among patients with ALD post-2011. We performed sensitivity analyses to account for any differences by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholic steatohepatitis, or Medicare insurance. We also performed a sensitivity analysis to account for any difference by prevalence of ALD among restrictive versus unrestrictive states. Of 10,836 LT recipients in 2002-2017, 7,091 were from 24 states in the restrictive group and 3,745 from 14 states in the unrestrictive group. The adjusted proportion (95% confidence interval) of LTs paid by Medicaid among restrictive versus unrestrictive states between 2002 and 2011 was 17.6% (15.4%-19.8%) versus 18.9% (15.4%-22.3%) (P = 0.54) and between 2012 and 2017, 17.2% (14.7%-19.7%) versus 23.2% (19.8%-26.6%) (P = 0.005). In difference-of-differences analysis, restrictive (versus unrestrictive) policies were associated with a 4.7% (0.8%-8.6%) (P = 0.02) absolute lower adjusted proportion of LTs for ALD paid by Medicaid post-2011. Conclusions Restrictive Medicaid policies are present in most states with active LT centers and are associated with lower proportions of LTs for ALD paid by Medicaid post-2011 compared to states with unrestrictive Medicaid policies. Reevaluation of Medicaid alcohol use policies may be warranted, to align more closely with contemporary center-level practices.
引用
收藏
页码:130 / 139
页数:10
相关论文
共 50 条
  • [21] Changing Times in Liver Transplantation for Alcohol-Associated Liver Disease
    Mitchell, Mack C.
    Maddrey, Willis C.
    JAMA INTERNAL MEDICINE, 2019, 179 (03) : 348 - 350
  • [22] Alcohol Use Disorder and Alcohol-Associated Liver Disease
    Ramkissoon, Resham
    Shah, Vijay H.
    ALCOHOL RESEARCH-CURRENT REVIEWS, 2022, 42 (01):
  • [23] Recidivism and post-transplant outcomes in patients with alcohol-associated liver disease
    Najafian, Nilofar
    Kagbo-Kue, Suaka
    Punukollu, Rachana
    Liu, Margaret C.
    Budvytyte, Laura
    Li, Xingjie
    McGary, Alyssa K.
    Chascsa, David M. H.
    Jadlowiec, Caroline
    Jayasekera, Channa
    Barnhill, Michele S.
    Dickson, Rolland
    JOURNAL OF HEPATOLOGY, 2024, 80 : S152 - S153
  • [24] The lymphatic system in alcohol-associated liver disease
    Kondo, Reiichiro
    Iwakiri, Yasuko
    CLINICAL AND MOLECULAR HEPATOLOGY, 2020, 26 (04) : 633 - 638
  • [25] Advances in the management of alcohol-associated liver disease
    Anouti, Ahmad
    Kerr, Thomas A.
    Mitchell, Mack C.
    Cotter, Thomas G.
    GASTROENTEROLOGY REPORT, 2024, 12
  • [26] Dietary cholesterol in alcohol-associated liver disease
    Jia, Lin
    IMMUNOMETABOLISM, 2023, 5 (02) : E00026
  • [27] Rifaximin-α in alcohol-associated liver disease
    Xie, Chencheng
    Singal, Ashwani K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06): : 495 - 497
  • [28] Gut Microbiome and Alcohol-associated Liver Disease
    Philips, Cyriac A.
    Schnabl, Bernd
    Bajaj, Jasmohan S.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (05) : 1349 - 1359
  • [29] Inflammation in alcohol-associated liver disease progression
    Lotersztajn, Sophie
    Riva, Antonio
    Wang, Sai
    Dooley, Steven
    Chokshi, Shilpa
    Gao, Bin
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (01): : 58 - 66
  • [30] IMPACT OF SOCIAL DETERMINANTS OF HEALTH ON TRANSPLANT CANDIDACY FOR ALCOHOL-ASSOCIATED LIVER DISEASE
    Malik, Avni
    Ouyang, Vivian
    Sterling, Richard
    Wedd, Joel
    HEPATOLOGY, 2024, 80